Taiwan · Delayed Price · Currency is TWD Syngen Biotech Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 3.59 billion. The enterprise value is 3.59 billion.
| Market Cap | 3.59B |
| Enterprise Value | 3.59B |
Important Dates
The last earnings date was Tuesday, October 28, 2025.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | Jun 26, 2025 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has decreased by -0.04% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 8.15% |
| Owned by Institutions (%) | 3.27% |
| Float | 10.54M |
Valuation Ratios
The trailing PE ratio is 12.30.
| PE Ratio | 12.30 |
| Forward PE | n/a |
| PS Ratio | 1.68 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | 10.61 |
| P/OCF Ratio | 9.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.43, with an EV/FCF ratio of 10.61.
| EV / Earnings | 12.29 |
| EV / Sales | 1.68 |
| EV / EBITDA | 7.43 |
| EV / EBIT | 9.93 |
| EV / FCF | 10.61 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.06 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.59 |
| Debt / FCF | 0.84 |
| Interest Coverage | 54.42 |
Financial Efficiency
Return on equity (ROE) is 12.94% and return on invested capital (ROIC) is 8.55%.
| Return on Equity (ROE) | 12.94% |
| Return on Assets (ROA) | 7.34% |
| Return on Invested Capital (ROIC) | 8.55% |
| Return on Capital Employed (ROCE) | 14.23% |
| Revenue Per Employee | 8.63M |
| Profits Per Employee | 1.18M |
| Employee Count | 247 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 4.23 |
Taxes
In the past 12 months, Syngen Biotech has paid 68.01 million in taxes.
| Income Tax | 68.01M |
| Effective Tax Rate | 18.88% |
Stock Price Statistics
The stock price has decreased by -3.99% in the last 52 weeks. The beta is 0.08, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -3.99% |
| 50-Day Moving Average | 126.53 |
| 200-Day Moving Average | 126.24 |
| Relative Strength Index (RSI) | 58.37 |
| Average Volume (20 Days) | 46,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.13 billion and earned 292.15 million in profits. Earnings per share was 10.77.
| Revenue | 2.13B |
| Gross Profit | 759.86M |
| Operating Income | 356.82M |
| Pretax Income | 360.16M |
| Net Income | 292.15M |
| EBITDA | 462.96M |
| EBIT | 356.82M |
| Earnings Per Share (EPS) | 10.77 |
Balance Sheet
The company has 283.17 million in cash and 283.73 million in debt, giving a net cash position of -561,000 or -0.02 per share.
| Cash & Cash Equivalents | 283.17M |
| Total Debt | 283.73M |
| Net Cash | -561,000 |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | 2.33B |
| Book Value Per Share | 86.21 |
| Working Capital | 598.39M |
Cash Flow
In the last 12 months, operating cash flow was 388.16 million and capital expenditures -49.64 million, giving a free cash flow of 338.52 million.
| Operating Cash Flow | 388.16M |
| Capital Expenditures | -49.64M |
| Free Cash Flow | 338.52M |
| FCF Per Share | 12.49 |
Margins
Gross margin is 35.65%, with operating and profit margins of 16.74% and 13.71%.
| Gross Margin | 35.65% |
| Operating Margin | 16.74% |
| Pretax Margin | 16.90% |
| Profit Margin | 13.71% |
| EBITDA Margin | 21.72% |
| EBIT Margin | 16.74% |
| FCF Margin | 15.88% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.79%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 3.79% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.38% |
| Buyback Yield | 0.04% |
| Shareholder Yield | 3.77% |
| Earnings Yield | 8.14% |
| FCF Yield | 9.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 4.77 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.77 |
| Piotroski F-Score | 7 |